In a surprise announcement on Tuesday, it was revealed the US Food and Drug Administration Commissioner Scott Gottlieb would be stepping down from the post, in one month.
There was no explanation given for the decision, to abandon the position, which Dr Gottlieb took on just two years ago, with strong evidence of moving forward legislation on speeding up new drug as well as generics and biosimilars approval, among other things.
However, in a note tweeted by the FDA's official Twitter account, Dr Gottlieb cited family as the principal reason behind his decision.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze